Education
About Us
Working with TipRanks
Follow Us
Personalis Inc (PSNL)
NASDAQ:PSNL
Earnings Data
Report Date
May 06, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.27Last Year’s EPS
-0.18Same Quarter Last Year
Strong Buy
Based on 7 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong commercial and clinical momentum (massive Clinical test growth, nearly 240% MRD biopharma revenue increase, two Medicare coverage wins, deepening evidence base and product innovation) alongside an intentional, transitional financial profile (legacy revenue wind-downs, margin compression from unreimbursed volume, higher operating losses and increased cash burn as the company scales). Management presented a clear strategy to trade near-term margins and higher cash usage for accelerated market share and reimbursement conversion, supported by a strong cash position and multiple validation points. Upside depends on further reimbursement rollouts (e.g., IO) and steady biopharma demand/timing.Company Guidance
Explosive Clinical Volume Growth
Delivered 6,183 Clinical tests in Q4 2025 (41% sequential growth vs Q3; 329% year-over-year). Full year 2025 Clinical volume exceeded 16,000 tests (394% YoY growth). 2026 volume guidance: 43,000–45,000 tests (~170% growth YoY; company expects Clinical volumes to roughly quadruple).
Substantial MRD Biopharma Momentum
MRD biopharma revenue grew nearly 240% year-over-year in 2025. Full-year biopharma revenue was $49.0M (slight decline from $51.0M due to expected trial wind-downs). Company expects MRD biopharma revenue of $20M–$21M in 2026 and strategic revenue to grow from approximately $14M in 2025 to $30M–$32M in 2026 (~121% projected growth).
Medicare Coverage Wins
Achieved two Medicare coverage decisions (breast cancer and lung cancer surveillance) with favorable pricing, enabling initial reimbursed Clinical revenue and strengthening market legitimacy. Additional MolDX dossier under review for immunotherapy monitoring (IO).
Strong Cash and Liquidity Position
Ended Q4 2025 with $240M of cash and short-term investments, no material debt beyond small equipment loans. Used ~$74M of cash in 2025; plans to use approximately $100M in 2026 to accelerate market share—implying roughly 2.5 years of runway at current burn guidance.
Product Innovation and Robust Evidence Base
Introduced a real-time variant tracker module (opt-in) for NeXT Personal; early access feedback positive. Built strong clinical evidence with landmark studies (TRACERx, Royal Marsden, VHIO, UCSD I-PREDICT) and has 35+ ongoing studies, plus B-STRONGER-1 enrollment >200—supporting clinical adoption and reimbursement efforts.
Commercial Traction and Partnerships
More than 900 oncologists ordering NeXT Personal. Expanded partnership with Tempus to include colorectal cancer (CRC). Commercial footprint includes 10 dedicated reps with plans to roughly double sales reps to accelerate penetration and deepen account usage.
Guidance Reflects Scaling Strategy
2026 guidance: total revenue $78M–$80M; expected gross margin 15%–20% (Q1 possibly lowest); net loss ~ $105M. Management frames the guidance as deliberate investment to scale Clinical volume and convert volume to higher-margin reimbursed revenue over time.
PSNL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
PSNL Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 26, 2026 | $9.03 | ― | ― |
Nov 04, 2025 | $8.73 | $7.66 | -12.26% |
Aug 05, 2025 | $5.64 | $4.40 | -21.99% |
May 06, 2025 | $4.00 | $4.84 | +21.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Personalis Inc (PSNL) report earnings?
Personalis Inc (PSNL) is schdueled to report earning on May 06, 2026, After Close (Confirmed).
What is Personalis Inc (PSNL) earnings time?
Personalis Inc (PSNL) earnings time is at May 06, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PSNL EPS forecast?
PSNL EPS forecast for the fiscal quarter 2026 (Q1) is -0.27.